Drug intelligence / Profile preview

AmnioStem

Development stage: Unknown
Lead developer: Creative Medical Technology
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

AmnioStem is an allogeneic, universal donor stem cell product composed of multipotent amniotic fetal stem cells derived from amniotic fluid. Developed by Creative Medical Technology Holdings (CMT) through a license from the University of California, San Diego, the platform is being evaluated for its regenerative and anti-inflammatory properties. The cells are believed to suppress pro-inflammatory cytokines, specifically TNF-alpha, which makes them a candidate for treating cancer-associated cachexia, stroke, and neurodegenerative disorders. Additionally, the company is exploring its potential in oncology, specifically for glioma, due to purported direct anti-cancer effects.

Brand names: AmnioStem
Other names: multipotent amniotic fetal stem cells

Beyond the preview

Go deeper on AmnioStem.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AmnioStem.

Explore the full profile